About Impel Pharmaceuticals
Impel Pharmaceuticals is a company based in Seattle (United States) founded in 2008 was acquired by Jn Bidco in January 2024. Impel Pharmaceuticals has raised $67.5 million across 6 funding rounds from investors including KKR, HHS and Norwest Venture Partners. Impel Pharmaceuticals offers products and services including Trudhesa and Precision Olfactory Delivery Technology. Impel Pharmaceuticals operates in a competitive market with competitors including Blue Rock Therapeutics, CellCarta, Ascend, RiboPro and Invivyd, among others.
- Headquarter Seattle, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Impel Pharmaceuticals Inc
-
Annual Revenue
$12.65 M (USD)1794as on Dec 31, 2022
-
Net Profit
-$106.31 M (USD)-39as on Dec 31, 2022
-
EBITDA
-$83.18 M (USD)-16as on Dec 31, 2022
-
Total Equity Funding
$67.5 M (USD)
in 6 rounds
-
Latest Funding Round
$67.5 M (USD), Series D
Dec 06, 2018
-
Investors
KKR
& 6 more
-
Employee Count
Not available
-
Acquired by
Jn Bidco
(Jan 03, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Impel Pharmaceuticals
Impel Pharmaceuticals offers a comprehensive portfolio of products and services, including Trudhesa and Precision Olfactory Delivery Technology.
Treats acute migraine with or without aura in adults.
Enables targeted upper nasal drug absorption for better efficacy.
People of Impel Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Impel Pharmaceuticals
Impel Pharmaceuticals has successfully raised a total of $67.5M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $67.5 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Impel Pharmaceuticals
Impel Pharmaceuticals has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include KKR, HHS and Norwest Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this private equity firm.
|
Locked | Locked | Locked | |
|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
|
Locked | Locked | Locked | |
|
Venture capital and private equity firm
|
Locked | Locked | Locked |
Investor details for Impel Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Impel Pharmaceuticals
Investment portfolio details for Impel Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Impel Pharmaceuticals
Detailed financials for Impel Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Impel Pharmaceuticals Comparisons
Peer comparison for Impel Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Impel Pharmaceuticals
Impel Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Blue Rock Therapeutics, CellCarta, Ascend, RiboPro and Invivyd, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Stem cell therapies are developed for cardiovascular and neurological diseases.
|
|
| Locked | Locked | Locked |
Histopathology and genomics services are offered by the CRO.
|
|
| Locked | Locked | Locked |
Online insurance payments and premium financing are enabled for businesses.
|
|
| Locked | Locked | Locked |
Online supplier and developer of RNA based products
|
|
| Locked | Locked | Locked |
Stem cell drug research and clinical trial services are provided.
|
Detailed competitors of Impel Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Impel Pharmaceuticals
Complete news archive for Impel Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Impel Pharmaceuticals
Impel Pharmaceuticals was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Impel Pharmaceuticals is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Leonard S Paolillo is the current CEO of Impel Pharmaceuticals.
Impel Pharmaceuticals is a funded company, having raised a total of $67.5M across 6 funding rounds to date.
Annual revenue of Impel Pharmaceuticals is $12.65M as on Dec 31, 2022.
Impel Pharmaceuticals was established in 2008 and is based in Seattle, United States. Operations are centered in the pharmaceutical sector, with emphasis placed on the development and commercialization of innovative therapies. Services are provided for advancing medical treatments from concept to market. The company is led by CEO Leonard S. Paolillo, supporting therapeutic solutions across various health applications.
Impel Pharmaceuticals's top competitors include Blue Rock Therapeutics, Ascend and CellCarta.
Impel Pharmaceuticals offers Trudhesa and Precision Olfactory Delivery Technology.
Impel Pharmaceuticals has 7 investors. Key investors include KKR, HHS, Norwest Venture Partners, Vivo Capital, and 5AM Ventures.